|Table of Contents|

The prognostic value of serum LncRNA MALAT1 and microRNA-124 levels in non-small cell lung cancer patients

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 07
Page:
1254-1259
Research Field:
Publishing date:

Info

Title:
The prognostic value of serum LncRNA MALAT1 and microRNA-124 levels in non-small cell lung cancer patients
Author(s):
LIANG Yahai; LI Jinmei; PENG Xiaoxia; ZHANG Lihua; LIU Meilian; ZHENG Weizhen; YANG Zhixiong; LAI Zhennan
Department of Lung Cancer,Affiliated Hospital of Guangdong Medical University,Guangdong Zhanjiang 524000,China.
Keywords:
non small cell lung cancer; long non-coding RNA; metastasis-associated lung adenocarcinoma transcript 1; microRNA-124; prognosis; forecast
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2024.07.012
Abstract:
Objective:To exploring the predictive efficacy of long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1(LncRNA MALAT1) combined with microRNA-124 in predicting the prognosis of non-small cell lung cancer(NSCLC) patients.Methods:124 NSCLC patients admitted to in our hospital between June 2020 and June 2022 were selected as the study subjects.After admission,the patient's medical records were collected and the relative expression of LncRNA MALAT1 and microRNA-124 in peripheral blood was detected.Record the mortality rate of patients during a 12 month follow-up by phone,divide them into survival group and death group,analyze the influencing factors of prognosis in NSCLC patients,and evaluate the predictive efficacy of serum LncRNA MALAT1 and microRNA-124 on the prognosis of NSCLC patients.Results:The proportion of patients in stage IV and the relative expression of LncRNA MALAT1 in the death group were higher than those in the survival group,while the relative expression of microRNA-124 was lower than that in the survival group.Logistic stepwise analysis showed that pathological stage IV(OR=12.342,95%CI:4.295~36.765),LncRNA MALAT1(OR=5.371,95%CI:1.836~15.714),and microRNA-124(OR=0.257,95%CI:0.089~0.752) were influencing factors for mortality in NSCLC patients(P＜0.05).There was a negative correlation between LncRNA MALAT1 and microRNA-124(P＜0.05).The receiver operating characteristic curve (ROC) analysis showed that the sensitivity of LncRNA MALAT1 and microRNA-124 in predicting the prognosis of NSCLC patients was 0.741(95%CI:0.601~0.846),0.759(95%CI:0.621~0.861),0.815(95%CI:0.682~0.903),and the specificity was 0.825(95%CI:0.705~0.906),0.762(95%CI:0.635~0.856),and 0.841(95%CI:0.723~0.917),respectively.The area under the curve(AUC) is 0.781,0.760,and 0.839,respectively.The joint prediction efficiency was higher(P＜0.05).Conclusion:LncRNA MALAT1 and microRNA-124 can be used to predict the prognosis of NSCLC patients,and their predictive efficacy is good.

References:

[1] TSAPONAS G,KOULOURIS A,KAZMIERCZAK D,et al.Matched analyses of brain metastases versus primary non-small cell lung cancer reveal a unique microRNA signature［J］.Int J Mol Sci,2022,24(1):193.
[2]陈梦雷,袁帅,周玫余,等.长链非编码RNA SFTA1P在肺腺癌中的表达及预后预测研究［J］.第三军医大学学报,2020,42(21):2075-2080,2115. CHEN ML,YUAN S,ZHOU MY,et al.Expression and prognostic prediction of long chain non coding RNA SFTA1P in lung adenocarcinoma ［J］.Journal of the Third Military Medical University,2020,42(21):2075-20802115.
[3] 艾力江·多力坤,艾孜子·阿不来提,陈康.非小细胞肺癌病人血长链非编码RNA和微小RNA-191表达水平及临床意义［J］.临床外科杂志,2023,31(8):729-732. Alejandro Dorikun,Aziz Albrecht,CHEN K.Expression of long-chain non-coding RNA and microrna-191 in blood of non-small-cell lung carcinoma patients and its clinical significance［J］.Journal of Clinical Surgery,2023,31(8):729-732.
[4] 王琦苑,李成银,朱晶,等.非小细胞肺癌组织中lncRNA MNX1-AS1、miR-218-5p的表达及临床意义［J］.中国医药导报,2023,20(8):99-102,110. WANG QY,LI CY,ZHU J,et al.Expression and clinical significance of lncrnas MNX1-AS1 and miR-218-5p in non-small-cell lung carcinoma tissues［J］.Chinese Journal of Medicinal Guide,2023,20(8):99-102,110.
[5] TURCO C,ESPOSITO G,IAIZA A,et al.MALAT1-dependent HAS-ICCc-0076611 regulates translation rate in triple-negative breast cancer［J］.Commun Biol,2022,5(1):598.
[6] CHEN M,CAI D,GU H,et al.MALAT1 rs619586 A/G polymorphisms are associated with decreased risk of lung cancer［J］.Medicine(Baltimore),2021,100(12):e23716.
[7] TONG G,TONG W,HE R,et al.MALAT1 polymorphisms and lung cancer susceptibility in a Chinese northeast Han population［J］.Int J Med Sci,2022,19(8):1300-1306.
[8]彭焦武,孙承谋.miR-124a和miR-449a对非小细胞肺癌的诊断价值［J］.检验医学,2021,36(1):34-38. PENG JW,SUN CM.The diagnostic value of miR-124a and miR-449a in non-small cell lung cancer ［J］ .Laboratory Medicine,2021,36(1):34-38.
[9] LIU T,ZHU J,DU W,et al.AKT2 drives cancer progression and is negatively modulated by miR-124 in human lung adenocarcinoma［J］.Respir Res,2020,21(1):227.
[10] LUO L,WANG Y,HU P,et al.Long non-coding RNA metastasis associated lung adenocarcinoma transcript 1(MALAT1) promotes hypertension by modulating the hsa-mir-124-3p/nuclear receptor subfamily 3,group C,member 2(NR3C2) and hsa-mir-135a-5p/NR3C2 axis［J］.Med Sci Monit,2020,26(1):e920478.
[11] LIU S,YAN G,ZHANG J,et al.Knockdown of long noncoding RNA(lncRNA) metastasis-associated lung adenocarcinoma transcript 1(MALAT1) inhibits proliferation,migration,and invasion and promotes apoptosis by targeting miR-124 in retinoblastoma［J］.Oncol Res,2018,26(4):581-591.
[12] 中华医学会,中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肺癌临床诊疗指南(2019版)［J］.中华肿瘤杂志,2020,42(4):257-287. Chinese Medical Association,Oncology Branch of Chinese Medical Association,Journal of Chinese Medical.Association Clinical Diagnosis and Treatment Guidelines for Lung Cancer of the Chinese Medical Association(2019 Edition) ［J］.Chinese Journal of Oncology,2020,42(4):257-287.
[13] SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
[14]汪勇,孙宝林,朱骏,等.长链非编码RNA TDRG1表达对非小细胞肺癌预后判断的价值［J］.东南大学学报(医学版),2020,39(6):812-816. WANG Y,SUN BL,ZHU J,et al.The value of long chain non coding RNA TDRG1 expression in predicting prognosis of non-small cell lung cancer ［J］ .Journal of Southeast University(Medical Edition),2020,39(6):812-816.
[15]任革,罗璐,贾永军,等.基于lncRNA AL158206.1-ceRNA-miRNA-19a-3p对FOXP1的调控探索重楼皂苷Ⅶ抑制NSCLC细胞的分子机制［J］.中国病理生理杂志,2022,38(11):2028-2037. REN G,LUO L,JIA YJ,et al.Based on the regulation of FOXP1 by lncRNA AL158206.1 ceRNA miRNA 19a-3p,explore the molecular mechanism of paris saponin VII inhibiting NSCLC cells［J］.Chinese Journal of Pathophysiology,2022,38(11):2028-2037.
[16] ZHANG L,HU J,MESHKAT BI,et al.LncRNA MALAT1 modulates TGF-beta1-Induced EMT in Keratinocyte［J］.Int J Mol Sci,2021,22(21):11816.
[17] GOYAL B,YADAV S,AWASTHEE N,et al.Diagnostic,prognostic,and therapeutic significance of long non-coding RNA MALAT1 in cancer［J］.Biochim Biophys Acta Rev Cancer,2021,1875(2):188502.
[18] 茆艳,周国平.长链非编码RNA MALAT1与肿瘤性疾病相关性的研究进展 ［J］.现代肿瘤医学，2020,28(05):862-866. MAO Y,ZHOU GP.Research progress on the relationship between long non-coding RNA MALAT1 and neoplastic diseases［J］.Modern Oncology，2020,28(05):862-866.
[19] WANG D,ZHANG S,ZHAO M,et al.LncRNA MALAT1 accelerates non-small cell lung cancer progression via regulating miR-185-5p/MDM4 axis［J］.Cancer Med,2020,9(23):9138-9149.
[20] SANUKI R,YAMAMURA T.Tumor suppressive effects of miR-124 and its function in neuronal development［J］.Int J Mol Sci,2021,22(11):5919.
[21] WU J,LI L,ZHANG Y,et al.Decreased miR-124 contributes to the epithelial-mesenchymal transition phenotype formation of lung adenocarcinoma cells via targeting enhancer of zeste homolog 2［J］.Pathol Res Pract,2020,216(6):152976.
[22] ROZI R,ZHOU Y,RONG K,et al.miR-124-3p sabotages lncRNA MALAT1 stability to repress chondrocyte pyroptosis and relieve cartilage injury in osteoarthritis［J］.J Orthop Surg Res,2022,17(1):453.
[23] CHENG C,XU BL,SHENG JL,et al.LncRNA MALAT1 regulates proliferation and apoptosis of vascular smooth muscle cells by targeting miRNA-124-3p/PPARalpha axis［J］.Eur Rev Med Pharmacol Sci,2019,23(20):9025-9032.

Memo

Memo:
National Natural Science Foundation of China（No.81871883）;国家自然科学基金项目(编号：81871883)；广东省湛江市科技计划项目(编号：2020B01327)
Last Update: 2024-02-29